- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:00 | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Sa | Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting | 453 | GlobeNewswire (Europe) | Designed with our proprietary AI-Immunology platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune... ► Artikel lesen | |
| 21.11. | Evaxion A/S - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 20.11. | Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1 | 266 | GlobeNewswire (Europe) | Evaxion's AI-Immunology platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining... ► Artikel lesen | |
| 20.11. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.11. | Evaxion announce 2026 financial calendar | 284 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 12, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, announces its financial calendar... ► Artikel lesen | |
| 12.11. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| EVAXION Aktie jetzt für 0€ handeln | |||||
| 08.11. | Evaxion presents new immune data for AI-designed cancer vaccine | 1 | Investing.com | ||
| 07.11. | Evaxion präsentiert neue Immun-Daten für KI-gestützten Krebsimpfstoff | 1 | Investing.com Deutsch | ||
| 07.11. | Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 | 664 | GlobeNewswire (Europe) | New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the... ► Artikel lesen | |
| 06.11. | Evaxion Biotech ADS GAAP EPS of $0.01 beats by $0.02, revenue of $7.49M beats by $4.99M | 1 | Seeking Alpha | ||
| 06.11. | Evaxion announces business update and third quarter 2025 financial results | 249 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, November 6, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update... ► Artikel lesen | |
| 05.11. | What's Next: Evaxion Biotech's Earnings Preview | 1 | Benzinga.com | ||
| 03.11. | Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate | 970 | GlobeNewswire (Europe) | Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with
our AI-Immunology platformEVX-04 is a therapeutic cancer vaccine candidate... ► Artikel lesen | |
| 03.11. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.10. | Evaxion A/S to announce business update and third quarter 2025 financial results on November 6, 2025 | 532 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
| 30.10. | Evaxion raises $7.2 million, extending cash runway to second half of 2027 | 297 | GlobeNewswire (Europe) | Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter... ► Artikel lesen | |
| 27.10. | Evaxion names Helen Tayton-Martin as new CEO | 3 | Seeking Alpha | ||
| 27.10. | Evaxion A/S - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.10. | Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer | 314 | GlobeNewswire (Europe) | Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership dealsHer more than 30... ► Artikel lesen |
1 2 3 4 Weiter >>
76 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 85,55 | +3,51 % | Biontech Aktie: CureVac-Fusion vor entscheidender Abstimmung - lohnt sich jetzt das Aktien kaufen? | ||
| EVOTEC | 5,470 | -2,29 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| QIAGEN | 40,080 | -0,83 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,472 | +1,50 % | Morgen-Update: Curevac sorgt für Spannung - kommt bald die Entscheidung? | ||
| AMGEN | 282,00 | -0,46 % | BMO Capital Lifts Amgen (AMGN) Price Target as MariTide Outlook Strengthens | ||
| NOVAVAX | 5,979 | +0,83 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| STRYKER | 311,40 | -0,35 % | Stryker Appoints Spencer Stiles As President And COO | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK), Thursday announced the appointment of Spencer Stiles as President and Chief Operating Officer of the company, effective January 1, 2026.Stiles, who... ► Artikel lesen | |
| BIOGEN | 154,40 | -0,87 % | Institut: Alzheimer-Medikament Lecanemab von Biogen hat keinen Zusatznutzen | BERLIN/KÖLN (dpa-AFX) - Schlechte Nachrichten für den US-Hersteller Biogen und seinen japanischen Partner Eisai: Ein umfassender Report sieht keinen Beweis für einen Zusatznutzen ihres Alzheimer-Medikaments... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,000 | +1,63 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,064 | +1,05 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 247,99 | 0,00 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 31,200 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen |
EVAXION A/S ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVAXION A/S ADR finden Sie auf Wallstreet Online.